Nath Bio-Genes (India) Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals

Technical Trends: Mild Improvement but Still Bearish

The primary driver behind the recent rating change is a subtle improvement in the technical grade. The technical trend has shifted from a strongly bearish stance to a mildly bearish one. Key technical indicators present a mixed picture: the Moving Average Convergence Divergence (MACD) remains bearish on both weekly and monthly charts, while the Relative Strength Index (RSI) shows no clear signal. Bollinger Bands continue to indicate mild bearishness, and daily moving averages also suggest a mildly bearish trend.

However, some indicators hint at potential stabilisation. The Know Sure Thing (KST) indicator is mildly bullish on a monthly basis, and the Dow Theory reflects a mildly bullish weekly trend, though no clear monthly trend is established. On Balance Volume (OBV) shows no definitive trend on either timeframe. This combination of signals suggests that while the stock is not out of the woods technically, the downward momentum has somewhat eased, prompting a slight upgrade in technical grading.

Valuation: Attractive but Not Enough to Offset Risks

From a valuation perspective, Nath Bio-Genes presents a compelling case. The company’s Return on Capital Employed (ROCE) stands at a modest 5.8%, yet it boasts a very attractive Enterprise Value to Capital Employed ratio of 0.5. This indicates that the stock is trading at a significant discount relative to the capital it employs, and compared to its peers’ historical valuations, it remains undervalued.

Despite this, the valuation appeal is tempered by the company’s weak financial performance and deteriorating fundamentals. The Price/Earnings to Growth (PEG) ratio is 1.5, reflecting moderate growth expectations relative to earnings. While the stock price has declined by 11.56% over the past year, profits have increased by 4.8%, suggesting some operational resilience. Nonetheless, the valuation alone is insufficient to warrant a more positive rating given other concerns.

Financial Trend: Flat to Negative Performance Raises Concerns

Financially, Nath Bio-Genes has delivered a flat performance in the third quarter of fiscal year 2025-26. Profit Before Tax (PBT) excluding other income declined sharply to a loss of ₹1.95 crores, a fall of 158.91% compared to the previous quarter. Net Profit After Tax (PAT) also turned negative at ₹0.15 crores, down 105.5%. Cash and cash equivalents have dwindled to a low ₹0.74 crores at half-year, signalling liquidity constraints.

Long-term fundamentals remain weak, with an average ROCE of just 6.03%. Institutional investor participation has also decreased, with holdings dropping by 0.76% over the previous quarter to a mere 0.32%. This decline in institutional interest is notable, as these investors typically possess superior analytical resources and tend to exit companies with deteriorating fundamentals.

In terms of returns, the stock has underperformed key benchmarks. Over the last year, Nath Bio-Genes generated a negative return of 11.56%, while the Sensex gained 6.66%. Over three and five years, the stock’s returns of 7.21% and -45.58% respectively lag behind the Sensex’s 37.76% and 65.60%. This underperformance highlights the company’s challenges in delivering shareholder value over both short and long horizons.

Quality Assessment: Weak Fundamentals and Market Position

The company’s overall quality rating remains poor, reflected in its low Mojo Score of 31.0 and a downgrade in Mojo Grade from Strong Sell to Sell. The Market Capitalisation Grade stands at 4, indicating a relatively small market cap that may limit liquidity and investor interest. Nath Bio-Genes operates in the Agri-Seeds segment within the broader Other Agricultural Products sector, a space that demands consistent innovation and scale to maintain competitiveness.

Given the flat financial results, weak returns, and declining institutional interest, the company’s quality metrics do not inspire confidence. The downgrade in rating reflects these fundamental weaknesses, despite some technical stabilisation and valuation appeal.

Stock Price and Market Context

On 5 February 2026, Nath Bio-Genes closed at ₹153.85, up 3.26% from the previous close of ₹149.00. The stock’s 52-week high and low stand at ₹238.00 and ₹138.00 respectively, indicating a wide trading range and significant volatility. Today’s trading range was ₹147.95 to ₹153.85, showing some intraday strength.

Despite the recent price uptick, the stock’s long-term performance remains disappointing relative to broader market indices. Investors should weigh the modest technical improvements against the company’s persistent fundamental challenges before considering exposure.

Conclusion: Cautious Stance Recommended

In summary, Nath Bio-Genes (India) Ltd’s recent downgrade from Strong Sell to Sell reflects a complex interplay of factors. While technical indicators have improved slightly, the overall trend remains bearish. Valuation metrics offer some attraction, but these are overshadowed by weak financial results, poor long-term returns, and declining institutional interest.

Investors should approach the stock with caution, recognising that the company faces significant headwinds in both operational performance and market perception. Until Nath Bio-Genes can demonstrate sustained financial improvement and stronger technical momentum, the Sell rating remains appropriate.

MarketsMOJO’s comprehensive analysis underscores the importance of balancing technical signals with fundamental quality and valuation when assessing investment opportunities in the agricultural products sector.

Unlock special upgrade rates for a limited period. Start Saving Now →